Beta Amyloid 42 40 Ratio Biomarker is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The Amyloid-beta 42/40 Ratio is a critical CSF biomarker for Alzheimer's disease diagnosis and amyloid pathology detection. It reflects the relative abundance of amyloid-beta species in cerebrospinal fluid.
| Property | Value |
|---|---|
| Full Name | Amyloid-Beta 42/40 Ratio |
| Abbreviation | Aβ42/40 |
| Target | Amyloid plaque composition |
| Primary Source | Cerebrospinal Fluid (CSF) |
| Assay Methods | ELISA, Simoa, Lumipulse |
| Clinical Use | AD diagnosis, prodromal detection |
The Aβ42/40 ratio measures the relative concentrations of Aβ42 (more aggregation-prone) versus Aβ40 (more soluble). A decreased ratio indicates increased Aβ42 deposition in amyloid plaques.
| Status | CSF Aβ42/40 Ratio |
|---|---|
| Normal (Amyloid-) | > 0.09 |
| Intermediate | 0.06 - 0.09 |
| Abnormal (Amyloid+) | < 0.06 |
Note: Cut-offs vary by laboratory and assay
| Application | Sensitivity | Specificity |
|---|---|---|
| AD vs. Controls | 85-95% | 80-90% |
| MCI converter vs. non-converter | 75-85% | 70-80% |
| Amyloid PET concordance | 85-95% | 85-95% |
| Biomarker | What it Measures | Advantages |
|---|---|---|
| Aβ42/40 Ratio | Plaque burden in CSF | Early detection, less expensive |
| Aβ42 (absolute) | CSF Aβ42 | Simpler assay |
| Amyloid PET | Plaque burden in brain | Direct visualization |
| P-tau | AD pathology | Specific to AD |
The study of Beta Amyloid 42 40 Ratio Biomarker has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Hardy J, et al. Aβ42 and Alzheimer's disease. Nat Rev Neurosci. 2020. ↩︎
Blennow K, et al. CSF biomarkers for AD. Lancet Neurol. 2020. ↩︎
Zetterberg H, et al. Aβ42/40 ratio in CSF. Brain. 2019. ↩︎
Hansson O, et al. Aβ42/40 improves diagnostic accuracy. Alzheimers Dement. 2020. ↩︎
Jack CR Jr, et al. NIA-AA framework. Alzheimers Dement. 2018. ↩︎
Mattsson N, et al. Aβ42/40 in MCI. JAMA Neurol. 2019. ↩︎
Palmqvist S, et al. Aβ42/40 sensitivity and specificity. Neurology. 2020. ↩︎
Hansson O, et al. Combined biomarker model. EMBO Mol Med. 2020. ↩︎
Bateman RJ, et al. Aβ42/40 in familial AD. N Engl J Med. 2020. ↩︎
Stomrud E, et al. Aβ42/40 predicts progression. Neurology. 2021. ↩︎
Roe CM, et al. Preclinical screening. Alzheimers Dement. 2020. ↩︎
Skillback T, et al. Aβ42/40 in FTD. J Neurol Neurosurg Psychiatry. 2019. ↩︎
Wallin AK, et al. Aβ42/40 in VaD. Dement Geriatr Cogn Disord. 2020. ↩︎
Siderowf A, et al. Aβ42/40 in PDD. Mov Disord. 2020. ↩︎
Cummings J, et al. Aβ42/40 in clinical trials. Alzheimers Dement. 2020. ↩︎
Mintun MA, et al. Lecanemab trial design. Nature. 2021. ↩︎
Mintun MA, et al. Donanemab TRAILBLAZER-ALZ. N Engl J Med. 2021. ↩︎
Schindler SE, et al. Plasma Aβ42/40. Neurology. 2021. ↩︎
Zetterberg H, et al. Point-of-care CSF testing. Nat Rev Neurol. 2020. ↩︎
Karikari TK, et al. Multiplex biomarkers. Mol Psychiatry. 2020. ↩︎
Rozemuller AJ, et al. Population screening for AD. Acta Neuropathol. 2020. ↩︎